Suboptimal treatment adherence in bipolar disorder: Impact on clinical outcomes and functioning

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 89-94

  Montes, Jose Manuel ^a   Maurino, Jorge ^b   de Dios, Consuelo ^b   Medina, Esteban ^b  

^a Hospital Universitario del Sureste de Madrid   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Bipolar disorder; Functioning; Polarity; Subsyndromal symptoms; Treatment adherence

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; PATIENT SELECTION; QUESTIONNAIRE; SAMPLE SIZE; SUBOPTIMAL TREATMENT ADHERENCE; SUBSTANCE ABUSE;

EID: 84872814940     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Wittchen HU, Jacobi F, Rehm J, et al. Size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655-679.
2. Dean BB, Gerner D, Gerner RH. A systematic review evaluating healthrelated quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20:139-154.
3. Bagalman E, Yu-Isenberg KS, Durden E, Crivera C, Dirani R, Bunn WB. Indirect costs associated with nonadherence to treatment for bipolar disorder. J Occup Environ Med. 2010;52:478-485.
4. Sánchez-Moreno J, Martínez-Arán A, Tabarés-Seisdedos R, et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom. 2009;78:285-297.
5. Rosa AR, Reinares M, Michalak EE, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010;13:984-988.
6. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;7:5.
7. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Suppl 4:1-46.
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
9. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63:384-390.
10. Vieta E, Azorin JM, Bauer M, et al. Psychiatrists' perceptions of potential reasons for nonand partial adherence to medication: results of a survey in bipolar disorder from eight European countries. J Affect Disord. 2012;143:125-130.
11. Gonzalez-Pinto A, Reed C, Novick D, Bertsch J, Haro JM. Assessment of medication in a cohort of patients with bipolar disorder. Pharmacopsychiatry. 2010;43:263-270.
12. Teter CJ, Falone AE, Bakaian AM, Tu C, Ongür D, Weiss RD. Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder. Psychiatry Res. 2011;190:253-258.
13. Medina E, Salvà J, Ampudia R, Maurino J, Larumbe J. Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder. Patient Prefer Adherence. 2012;6:623-629.
14. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2013;127:23-33.
15. Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30:1358-1374.
16. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
17. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19:609-618.
18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24: 67-74.
19. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312: 345-349.
20. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow up. Br J Psychiatry. 1998;172:413-419.
21. Nielsen RE, Lindström E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012;22: 747-750.
22. Erickson SR, Coombs JH, Kirking DM, Azimi AR. Compliance from self-reported versus pharmacy claims data with metered-dose inhalers. Ann Pharmacother. 2001;35:997-1003.
23. Gray R, Leese M, Bindman J, et al. Adherence therapy for people with schizophrenia. Br J Psychiatry. 2006;189:508-514.
24. Montes JM, Medina E, Gómez-Beneyto M, Maurino J. A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Res. 2012;200:89-95.
25. Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London frst episode schizophrenia study. Acta Psychiatr Scand. 2003;108:439-446.
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
27. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
28. Vieta E, Torrent-Font C, Martínez-Arán A, et al. A user-friendly scale for the short and long term outcome of bipolar disorder: the CGI-BP-M. Actas Esp Psiquiatr. 2002;30:301-304.
29. Sajatovic M, Ignacio RV, West JA, et al. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry. 2009;50:100-107.
30. Martínez-Arán A, Scott J, Colom F, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry. 2009;70:1017-1023.
31. Linke J, Sönnekes C, Wessa M. Sensitivity to positive and negative feedback in euthymic patients with bipolar I disorder: the last episode makes the difference. Bipolar Disord. 2011;13:638-650.
32. De Dios C, Ezquiaga E, Garcia A, Soler B, Vieta E. Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: a prospective, 18-month follow-up study. J Affect Disord. 2010;125:74-81.
33. De Dios C, Ezquiaga E, Agud JL, Vieta E, Soler B, Garcia-Lopez A. Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients. J Affect Disord. 2012;143: 160-165.
34. Kikkert MJ, Barbui C, Koeter MWJ. Assessment of medication adherence in patients with schizophrenia. The Achilles heel of adherence research. J Nerv Ment Dis. 2008;196:274-281.
35. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in out-patients with severe mental disorders: relation between selfreports and serum level. J Clin Psychopharmacol. 2010;30:169-175.
36. Sajatovic M, Velligan DI, Weiden PJ, Valenstein MA, Ogedegbe G. Measurement of psychiatric treatment adherence. J Psychosom Res. 2010;69:591-599.
37. Colom F. Achieving remission and recovery in bipolar disorder. J Clin Psychiatry. 2010;71:e32.
38. Crowe M, Porter R, Inder M, Lacey C, Carlyle D, Wilson L. Effectiveness of interventions to improve medication adherence in bipolar disorder. Aust N Z J Psychiatry. 2012;46:317-326.